Skip to Main Content

Top of the morning to you and a fine one, it is. Blue skies and crisp breezes are enveloping the serene Pharmalot campus this morning, where the short person remains hunched over a laptop and the official mascot is sprinting about the grounds in search of creatures. This means we are happily focused on the important matters at hand — brewing cups of stimulation (blueberry is our choice today) and foraging for items of interest. On that note, here are a few. May today be productive, satisfying, and safe. Meanwhile, do keep in touch. …

The Covid-19 vaccine developed by the University of Oxford and AstraZeneca (AZN) produces a strong immune response in healthy adults 56 to 69 years old and people over 70, The Telegraph telegraphs. Phase 2 data, published in The Lancet, suggests one of the groups most vulnerable to serious illness and death from Covid-19 could build immunity. There were also fewer serious side effects than in younger volunteers. Phase 3 trials of the vaccine are ongoing, with early efficacy readings possible in the coming weeks.


Securities and Exchange Commission Chairman Jay Clayton called for company insiders to avoid immediately trading after they set up plans to sell shares they have accumulated, following a spate of big-ticket stock sales by pharmaceutical executives, The Wall Street Journal writes. He suggested a “cooling-off period” for so-called 10b5-1 plans, which allow company executives to sell stock at a predetermined time — even if they are in possession of important nonpublic information — without exposing themselves to insider-trading charges.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!